QT Variability Pre and Post Cardioversion (DCCV)

This study has been completed.

Sponsor:

Vanderbilt University

ClinicalTrials.gov Identifier:

NCT00885391

First Posted: April 22, 2009

Last Update Posted: December 11, 2014

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Further study details as provided by Dawood Darbar, Vanderbilt University:

Primary Outcome Measures:

QT variability before and after direct current cardioversion [ Time Frame: 1.5 ]

Biospecimen Retention: Samples With DNA

Blood sample

Enrollment:

219

Study Start Date:

January 2007

Study Completion Date:

March 2012

Primary Completion Date:

March 2012 (Final data collection date for primary outcome measure)

Detailed Description:

Atrial Fibrillation variably activates the renin-angiotensin-aldosterone system (RAAS), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. These are interrelated responses and the extent to which these or other pathophysiologic responses determine QT interval during and after Atrial Fibrillation (AF) is unknown. In this study, the QT variability is related to those potential markers in patients with AF undergoing elective DC-cardioversion.

Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

21 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Sampling Method:

Probability Sample

Study Population

Cardiology Clinic Hospital inpatient

Criteria

Inclusion Criteria:

At least 21 years of age

Scheduled to undergo an elective DC-Cardioversion of atrial fibrillation or atrial flutter at Vanderbilt University Medical Center